CYP19 haplotypes increase risk for Alzheimer's disease
Journal of Medical Genetics
|August 3, 2006
Summary
Two specific gene variations (haplotypes) in the aromatase gene (CYP19) significantly increase Alzheimer's disease (AD) risk, particularly in individuals with the APOE 4 gene variant. Further research into brain aromatase regulation is needed.
Area of Science:
- Neurogenetics
- Enzymology
Background:
- Cytochrome P450 aromatase (CYP19) converts androgens to estrogens, with high expression in gonads and brain.
- Elevated aromatase activity in the nucleus basalis of Meynert is observed during aging and in Alzheimer's disease (AD).
- The CYP19 gene at 15q21.1 is a candidate risk factor for AD due to altered enzyme activity.
Discussion:
- The study investigated 18 single nucleotide polymorphisms (SNPs) across the CYP19 gene in 227 AD patients and 131 controls.
- The CYP19 gene region was divided into two haplotype blocks.
- Specific haplotypes within these blocks were associated with a twofold increased risk of AD in APOE 4 carriers.
Key Insights:
- Two specific haplotypes within the CYP19 gene confer an increased risk for developing Alzheimer's disease.
- This risk is significantly amplified in individuals carrying the APOE 4 gene variant.
- The findings highlight a potential genetic link between aromatase activity and AD pathogenesis.
Outlook:
- Further investigation into the regulatory mechanisms of aromatase activity in the brain is warranted.
- Exploring the functional consequences of these specific CYP19 haplotypes in AD is crucial.
- This research may open new avenues for understanding and potentially treating AD.
More Related Videos
04:41Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
Related Concept Videos
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:21Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...